Fever, Rash, and Systemic Symptoms: Understanding the Role of Virus and HLA in Severe Cutaneous Drug Allergy

Pirmohamed, 2011, The phenotype standardization project: improving pharmacogenetic studies of serious adverse drug reactions, Clin Pharmacol Ther, 89, 784, 10.1038/clpt.2011.30

Hotz, 2013, Systemic involvement of acute generalized exanthematous pustulosis: a retrospective study on 58 patients, Br J Dermatol, 169, 1223, 10.1111/bjd.12502

Sidoroff, 2001, Acute generalized exanthematous pustulosis (AGEP): a clinical reaction pattern, J Cutan Pathol, 28, 113, 10.1034/j.1600-0560.2001.028003113.x

Speeckaert, 2010, Acute generalized exanthematous pustulosis: an overview of the clinical, immunological and diagnostic concepts, Eur J Dermatol, 20, 425, 10.1684/ejd.2010.0932

Raison-Peyron, 2013, “Cutaneous adverse drug reactions” are not always drug-induced, Eur J Dermatol, 23, 439, 10.1684/ejd.2013.2055

Feio, 1997, Acute generalized exanthematous pustulosis due to Coxsackie B4 virus [in Portuguese], Acta Med Port, 10, 487

Haro-Gabaldon, 1996, Acute generalized exanthematous pustulosis with cytomegalovirus infection, Int J Dermatol, 35, 735, 10.1111/j.1365-4362.1996.tb00653.x

Klein, 2009, Acute generalized exanthematous pustulosis associated with recurrent urinary tract infections [in German with English abstract], Hautarzt, 60, 226, 10.1007/s00105-008-1604-1

Manzano, 2006, Acute generalized exanthematous pustulosis: first case associated with a Chlamydia pneumoniae infection [in French with English abstract ], Arch Pediatr, 13, 1230, 10.1016/j.arcped.2006.06.004

Naides, 1998, Rheumatic manifestations of parvovirus B19 infection, Rheum Dis Clin North Am, 24, 375, 10.1016/S0889-857X(05)70014-4

Bernard, 1995, HLA et prédisposition génétique dans les pustuloses exanthématiques aiguës généralisées (PEAG) et dans les exanthèmes maculo-papuleux (EMP), Ann Dermatol Venereol, 122, S38

Tohyama, 2011, New aspects of drug-induced hypersensitivity syndrome, J Dermatol, 38, 222, 10.1111/j.1346-8138.2010.01176.x

Tohyama, 2007, Association of human herpesvirus 6 reactivation with the flaring and severity of drug-induced hypersensitivity syndrome, Br J Dermatol, 157, 934, 10.1111/j.1365-2133.2007.08167.x

Pavlos, 2012, HLA and pharmacogenetics of drug hypersensitivity, Pharmacogenomics, 13, 1285, 10.2217/pgs.12.108

Martin, 2005, Predisposition to nevirapine hypersensitivity associated with HLA-DRB1*0101 and abrogated by low CD4 T-cell counts, AIDS, 19, 97, 10.1097/00002030-200501030-00014

Phillips EBJ, Sanne I, Lederman M, Hinkle J, Rousseau F, James I, et al. Associations between HLA-DRBA*0102, HLA-B*5801 and hepatotoxicity in patients who initiated nevirapine containing regimens in South Africa. 18th Conference on retroviruses and opportunistic infections. Paper #949. Boston, MA; February 2011.

Yuan, 2011, Toxicogenomics of nevirapine-associated cutaneous and hepatic adverse events among populations of African, Asian, and European descent, AIDS, 25, 1271, 10.1097/QAD.0b013e32834779df

Phillips, 2013, Associations between HLA-DRB1*0102, HLA-B*5801, and hepatotoxicity during initiation of nevirapine-containing regimens in South Africa, J Acquir Immune Defic Syndr, 62, e55, 10.1097/QAI.0b013e31827ca50f

Littera, 2006, HLA-dependent hypersensitivity to nevirapine in Sardinian HIV patients, AIDS, 20, 1621, 10.1097/01.aids.0000238408.82947.09

Gatanaga, 2007, HLA-Cw8 primarily associated with hypersensitivity to nevirapine, AIDS, 21, 264, 10.1097/QAD.0b013e32801199d9

Gao, 2011, HLA-dependent hypersensitivity reaction to nevirapine in chinese han hiv-infected patients, AIDS Res Hum Retroviruses, 28, 540, 10.1089/aid.2011.0107

Carr, 2013, Association of human leukocyte antigen alleles and nevirapine hypersensitivity in a Malawian HIV-infected population, Clin Infect Dis, 56, 1330, 10.1093/cid/cit021

Cutrell, 2004, Updated clinical risk factor analysis of suspected hypersensitivity reactions to abacavir, Ann Pharmacother, 38, 2171, 10.1345/aph.1E202

Symonds, 2002, Risk factor analysis of hypersensitivity reactions to abacavir, Clin Ther, 24, 565, 10.1016/S0149-2918(02)85132-3

Hetherington, 2002, Genetic variations in HLA-B region and hypersensitivity reactions to abacavir, Lancet, 359, 1121, 10.1016/S0140-6736(02)08158-8

Mallal, 2002, Association between presence of HLA-B*5701, HLA-DR7, and HLA-DQ3 and hypersensitivity to HIV-1 reverse-transcriptase inhibitor abacavir, Lancet, 359, 727, 10.1016/S0140-6736(02)07873-X

Phillips, 2005, Clinical and immunogenetic correlates of abacavir hypersensitivity, AIDS, 19, 979, 10.1097/01.aids.0000171414.99409.fb

Mallal, 2008, HLA-B*5701 screening for hypersensitivity to abacavir, N Engl J Med, 358, 568, 10.1056/NEJMoa0706135

Phillips ESS, Arribas J, Fitch N, Givens N. Characteristics of abacavir hypersensitivity diagnoses according to HLA-B*5701 status and subsequent abacavir patch test result. 11th European AIDS Conference. Madrid, Spain. 2007:P9.7/04.

Saag, 2008, High sensitivity of human leukocyte antigen-b*5701 as a marker for immunologically confirmed abacavir hypersensitivity in white and black patients, Clin Infect Dis, 46, 1111, 10.1086/529382

Martin, 2012, Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing, Clin Pharmacol Ther, 91, 734, 10.1038/clpt.2011.355

Hughes, 2004, Cost-effectiveness analysis of HLA B*5701 genotyping in preventing abacavir hypersensitivity, Pharmacogenetics, 14, 335, 10.1097/00008571-200406000-00002

Schackman, 2008, The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV, AIDS, 22, 2025, 10.1097/QAD.0b013e3283103ce6

Phillips, 2002, Utility of patch testing in patients with hypersensitivity syndromes associated with abacavir, AIDS, 16, 2223, 10.1097/00002030-200211080-00017

Almeida, 2008, Cytokine profiling in abacavir hypersensitivity patients, Antivir Ther, 13, 281, 10.1177/135965350801300202

Martin, 2007, Immune responses to abacavir in antigen-presenting cells from hypersensitive patients, AIDS, 21, 1233, 10.1097/QAD.0b013e3280119579

Chessman, 2008, Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity, Immunity, 28, 822, 10.1016/j.immuni.2008.04.020

Chung, 2004, Medical genetics: a marker for Stevens-Johnson syndrome, Nature, 428, 486, 10.1038/428486a

Hung, 2006, Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions, Pharmacogenet Genomics, 16, 297, 10.1097/01.fpc.0000199500.46842.4a

Kulkantrakorn, 2011, HLA-B*1502 Strongly predicts carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Thai patients with neuropathic pain, Pain Pract, 12, 202, 10.1111/j.1533-2500.2011.00479.x

Likanonsakul, 2009, HLA-Cw*04 allele associated with nevirapine-induced rash in HIV-infected Thai patients, AIDS Res Ther, 6, 22, 10.1186/1742-6405-6-22

Mehta, 2009, Association of HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome among Indians, Indian J Dermatol Venereol Leprol, 75, 579, 10.4103/0378-6323.57718

Tassaneeyakul, 2010, Association between HLA-B*1502 and carbamazepine-induced severe cutaneous adverse drug reactions in a Thai population, Epilepsia, 51, 926, 10.1111/j.1528-1167.2010.02533.x

Then, 2011, Frequency of the HLA-B*1502 allele contributing to carbamazepine-induced hypersensitivity reactions in a cohort of Malaysian epilepsy patients, Asian Pac J Allergy Immunol, 29, 290

Kim, 2011, Carbamazepine-induced severe cutaneous adverse reactions and HLA genotypes in Koreans, Epilepsy Res, 97, 190, 10.1016/j.eplepsyres.2011.08.010

Chen, 2011, Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan, N Engl J Med, 364, 1126, 10.1056/NEJMoa1009717

Amstutz, 2013, HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children, Clin Pharmacol Ther, 94, 142, 10.1038/clpt.2013.55

McCormack, 2011, HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans, N Engl J Med, 364, 1134, 10.1056/NEJMoa1013297

Ozeki, 2011, Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in a Japanese population, Hum Mol Genet, 20, 1034, 10.1093/hmg/ddq537

Ko, 2011, Shared and restricted T-cell receptor use is crucial for carbamazepine-induced Stevens-Johnson syndrome, J Allergy Clin Immunol, 128, 1266, 10.1016/j.jaci.2011.08.013

Park, 2001, Metabolic activation in drug allergies, Toxicology, 158, 11, 10.1016/S0300-483X(00)00397-8

Pichler, 2006, Pharmacological interaction of drugs with immune receptors: the p-i concept, Allergol Int, 55, 17, 10.2332/allergolint.55.17

Illing, 2012, Immune self-reactivity triggered by drug-modified HLA-peptide repertoire, Nature, 486, 554, 10.1038/nature11147

Ostrov, 2012, Drug hypersensitivity caused by alteration of the MHC-presented self-peptide repertoire, Proc Natl Acad Sci U S A, 109, 9959, 10.1073/pnas.1207934109

Norcross, 2012, Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity, AIDS, 26, F21, 10.1097/QAD.0b013e328355fe8f

Wei, 2012, Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome, J Allergy Clin Immunol, 129, 1562, 10.1016/j.jaci.2011.12.990

Kano, 2004, Association between anticonvulsant hypersensitivity syndrome and human herpesvirus 6 reactivation and hypogammaglobulinemia, Arch Dermatol, 140, 183, 10.1001/archderm.140.2.183

Descamps, 2001, Association of human herpesvirus 6 infection with drug reaction with eosinophilia and systemic symptoms, Arch Dermatol, 137, 301

Kano, 2006, Several herpesviruses can reactivate in a severe drug-induced multiorgan reaction in the same sequential order as in graft-versus-host disease, Br J Dermatol, 155, 301, 10.1111/j.1365-2133.2006.07238.x

Seishima, 2006, Reactivation of human herpesvirus (HHV) family members other than HHV-6 in drug-induced hypersensitivity syndrome, Br J Dermatol, 155, 344, 10.1111/j.1365-2133.2006.07332.x

Shiohara, 2006, Drug-induced hypersensitivity syndrome (DIHS): a reaction induced by a complex interplay among herpesviruses and antiviral and antidrug immune responses, Allergol Int, 55, 1, 10.2332/allergolint.55.1

Picard, 2010, Drug reaction with eosinophilia and systemic symptoms (DRESS): a multiorgan antiviral T cell response, Sci Transl Med, 2, 10.1126/scitranslmed.3001116

Ushigome, 2013, Short- and long-term outcomes of 34 patients with drug-induced hypersensitivity syndrome in a single institution, J Am Acad Dermatol, 68, 721, 10.1016/j.jaad.2012.10.017

Aihara, 2001, Anticonvulsant hypersensitivity syndrome associated with reactivation of cytomegalovirus, Br J Dermatol, 144, 1231, 10.1046/j.1365-2133.2001.04239.x

Descamps, 2003, Drug-induced hypersensitivity syndrome associated with Epstein-Barr virus infection, Br J Dermatol, 148, 1032, 10.1046/j.1365-2133.2003.05330.x

Harding, 2012, Severe drug-induced hypersensitivity syndrome with a shared HLA-B allele, Med J Aust, 197, 411, 10.5694/mja12.10477

Aota, 2009, Systemic lupus erythematosus presenting with Kikuchi-Fujimoto's disease as a long-term sequela of drug-induced hypersensitivity syndrome. A possible role of Epstein-Barr virus reactivation, Dermatology, 218, 275, 10.1159/000187619

Chiou, 2006, Fulminant type 1 diabetes mellitus caused by drug hypersensitivity syndrome with human herpesvirus 6 infection, J Am Acad Dermatol, 54, S14, 10.1016/j.jaad.2005.03.057

Kano, 2007, Sclerodermoid graft-versus-host disease-like lesions occurring after drug-induced hypersensitivity syndrome, Br J Dermatol, 156, 1061, 10.1111/j.1365-2133.2007.07784.x

Sekine, 2001, Rapid loss of insulin secretion in a patient with fulminant type 1 diabetes mellitus and carbamazepine hypersensitivity syndrome, JAMA, 285, 1153, 10.1001/jama.285.9.1153

Takahashi, 2009, Defective regulatory T cells in patients with severe drug eruptions: timing of the dysfunction is associated with the pathological phenotype and outcome, J Immunol, 182, 8071, 10.4049/jimmunol.0804002

Chen, 2013, Long-term sequelae of drug reaction with eosinophilia and systemic symptoms: a retrospective cohort study from Taiwan, J Am Acad Dermatol, 68, 459, 10.1016/j.jaad.2012.08.009

Burrows, 1994, An alloresponse in humans is dominated by cytotoxic T lymphocytes (CTL) cross-reactive with a single Epstein-Barr virus CTL epitope: implications for graft-versus-host disease, J Exp Med, 179, 1155, 10.1084/jem.179.4.1155

Gamadia, 2004, Cross-reactivity of cytomegalovirus-specific CD8+ T cells to allo-major histocompatibility complex class I molecules, Transplantation, 77, 1879, 10.1097/01.TP.0000131158.81346.64

Koelle, 2002, Herpes simplex virus type 2-specific CD8 cytotoxic T lymphocyte cross-reactivity against prevalent HLA class I alleles, Blood, 99, 3844, 10.1182/blood.V99.10.3844

Landais, 2006, EBV-specific CD4+ T cell clones exhibit vigorous allogeneic responses, J Immunol, 177, 1427, 10.4049/jimmunol.177.3.1427

Amir, 2010, Allo-HLA reactivity of virus-specific memory T cells is common, Blood, 115, 3146, 10.1182/blood-2009-07-234906

D'Orsogna, 2011, Screening of viral specific T-cell lines for HLA alloreactivity prior to adoptive immunotherapy may prevent GvHD, Transpl Immunol, 24, 141, 10.1016/j.trim.2010.12.001

Morice, 2010, Cross-reactivity of herpesvirus-specific CD8 T cell lines toward allogeneic class I MHC molecules, PLoS One, 5, e12120, 10.1371/journal.pone.0012120

Amir, 2011, Allo-HLA-reactive T cells inducing graft-versus-host disease are single peptide specific, Blood, 118, 6733, 10.1182/blood-2011-05-354787

Deckers, 1998, Epithelial- and endothelial-cell specificity of renal graft infiltrating T cells, Clin Transplant, 12, 285

Yard, 1994, Recognition of a tissue-specific polymorphism by graft infiltrating T-cell clones isolated from a renal allograft with acute rejection, Nephrol Dial Transplant, 9, 805

Deckers, 1997, Tissue-specific characteristics of cytotoxic graft-infiltrating T cells during renal allograft rejection, Transplantation, 64, 178, 10.1097/00007890-199707150-00034

D'Orsogna, 2011, Tissue specificity of cross-reactive allogeneic responses by EBV EBNA3A-specific memory T cells, Transplantation, 91, 494, 10.1097/TP.0b013e318207944c

Schnyder, 2013, HLA-B*57:01(+) abacavir-naive individuals have specific T cells but no patch test reactivity, J Allergy Clin Immunol, 132, 756, 10.1016/j.jaci.2013.04.013

Mackay, 2012, Maintenance of T cell function in the face of chronic antigen stimulation and repeated reactivation for a latent virus infection, J Immunol, 188, 2173, 10.4049/jimmunol.1102719

Lang, 2009, Inflation and long-term maintenance of CD8 T cells responding to a latent herpesvirus depend upon establishment of latency and presence of viral antigens, J Immunol, 183, 8077, 10.4049/jimmunol.0801117

Lang, 2011, Functional CD8 T cell memory responding to persistent latent infection is maintained for life, J Immunol, 187, 3759, 10.4049/jimmunol.1100666

Allam, 2009, The CD8+ memory T-cell state of readiness is actively maintained and reversible, Blood, 114, 2121, 10.1182/blood-2009-05-220087

Brehm, 2002, T cell immunodominance and maintenance of memory regulated by unexpectedly cross-reactive pathogens, Nat Immunol, 3, 627, 10.1038/ni806

Gray, 1991, T cell memory is short-lived in the absence of antigen, J Exp Med, 174, 969, 10.1084/jem.174.5.969

Genin, 2011, Genome-wide association study of Stevens-Johnson syndrome and toxic epidermal necrolysis in Europe, Orphanet J Rare Dis, 6, 52, 10.1186/1750-1172-6-52

Hung, 2005, HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol, Proc Natl Acad Sci U S A, 102, 4134, 10.1073/pnas.0409500102

Lonjou, 2008, A European study of HLA-B in Stevens-Johnson syndrome and toxic epidermal necrolysis related to five high-risk drugs, Pharmacogenet Genomics, 18, 99, 10.1097/FPC.0b013e3282f3ef9c

Somkrua, 2011, Association of HLA-B*5801 allele and allopurinol-induced Stevens Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis, BMC Med Genet, 12, 118, 10.1186/1471-2350-12-118

Tassaneeyakul, 2009, Strong association between HLA-B*5801 and allopurinol-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in a Thai population, Pharmacogenet Genomics, 19, 704, 10.1097/FPC.0b013e328330a3b8

Cristallo, 2011, A study of HLA class I and class II 4-digit allele level in Stevens-Johnson syndrome and toxic epidermal necrolysis, Int J Immunogenet, 38, 303, 10.1111/j.1744-313X.2011.01011.x

Kang, 2011, Positive and negative associations of HLA class I alleles with allopurinol-induced SCARs in Koreans, Pharmacogenet Genomics, 21, 303, 10.1097/FPC.0b013e32834282b8

Ramasamy, 2013, Allopurinol hypersensitivity: a systematic review of all published cases, 1950-2012, Drug Saf, 36, 953, 10.1007/s40264-013-0084-0

Goncalo, 2013, HLA-B*58:01 is a risk factor for allopurinol-induced DRESS and Stevens-Johnson syndrome/toxic epidermal necrolysis in a Portuguese population, Br J Dermatol, 169, 660, 10.1111/bjd.12389

Locharernkul, 2008, Carbamazepine and phenytoin induced Stevens-Johnson syndrome is associated with HLA-B*1502 allele in Thai population, Epilepsia, 49, 2087, 10.1111/j.1528-1167.2008.01719.x

Man, 2007, Association between HLA-B*1502 allele and antiepileptic drug-induced cutaneous reactions in Han Chinese, Epilepsia, 48, 1015, 10.1111/j.1528-1167.2007.01022.x

Wang, 2011, Association between HLA-B*1502 allele and carbamazepine-induced severe cutaneous adverse reactions in Han people of southern China mainland, Seizure, 20, 446, 10.1016/j.seizure.2011.02.003

Wu, 2010, Association between carbamazepine-induced cutaneous adverse drug reactions and the HLA-B*1502 allele among patients in central China, Epilepsy Behav, 19, 405, 10.1016/j.yebeh.2010.08.007

Zhang, 2011, Strong association between HLA-B*1502 and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in mainland Han Chinese patients, Eur J Clin Pharmacol, 67, 885, 10.1007/s00228-011-1009-4

Chang, 2011, Association of HLA-B*1502 allele with carbamazepine-induced toxic epidermal necrolysis and Stevens-Johnson syndrome in the multi-ethnic Malaysian population, Int J Dermatol, 50, 221, 10.1111/j.1365-4632.2010.04745.x

Tangamornsuksan, 2013, Relationship between the HLA-B*1502 allele and carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis, JAMA Dermatol, 149, 1025, 10.1001/jamadermatol.2013.4114

Cheung, 2013, HLA-B alleles associated with severe cutaneous reactions to antiepileptic drugs in Han Chinese, Epilepsia, 54, 1307, 10.1111/epi.12217

Kaniwa, 2010, HLA-B*1511 is a risk factor for carbamazepine-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients, Epilepsia, 51, 2461, 10.1111/j.1528-1167.2010.02766.x

Ikeda, 2010, HLA class I markers in Japanese patients with carbamazepine-induced cutaneous adverse reactions, Epilepsia, 51, 297, 10.1111/j.1528-1167.2009.02269.x

Niihara, 2011, HLA-A31 strongly associates with carbamazepine-induced adverse drug reactions but not with carbamazepine-induced lymphocyte proliferation in a Japanese population, J Dermatol, 39, 594, 10.1111/j.1346-8138.2011.01457.x

Hung, 2010, Common risk allele in aromatic antiepileptic-drug induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Han Chinese, Pharmacogenomics, 11, 349, 10.2217/pgs.09.162

An, 2010, Association study of lamotrigine-induced cutaneous adverse reactions and HLA-B*1502 in a Han Chinese population, Epilepsy Res, 92, 226, 10.1016/j.eplepsyres.2010.10.006

Shi, 2011, Hla-B alleles and lamotrigine-induced cutaneous adverse drug reactions in the Han Chinese population, Basic Clin Pharmacol Toxicol, 109, 42, 10.1111/j.1742-7843.2011.00681.x

Kaniwa, 2013, Specific HLA types are associated with antiepileptic drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese subjects, Pharmacogenomics, 14, 1821, 10.2217/pgs.13.180

Roujeau, 1987, Genetic susceptibility to toxic epidermal necrolysis, Arch Dermatol, 123, 1171, 10.1001/archderm.1987.01660330082014

Lee, 2009, Strontium ranelate-induced toxic epidermal necrolysis in a patient with post-menopausal osteoporosis, Osteoporos Int, 20, 161, 10.1007/s00198-008-0677-0

Musette, 2010, Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity, Osteoporos Int, 21, 723, 10.1007/s00198-009-1097-5

Kaniwa, 2008, HLA-B locus in Japanese patients with anti-epileptics and allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis, Pharmacogenomics, 9, 1617, 10.2217/14622416.9.11.1617

Tohkin, 2011, A whole-genome association study of major determinants for allopurinol-related Stevens-Johnson syndrome and toxic epidermal necrolysis in Japanese patients, Pharmacogenomics J, 13, 60, 10.1038/tpj.2011.41

Chiu, 2012, Association between HLA-B*58:01 allele and severe cutaneous adverse reactions with allopurinol in Han Chinese in Hong Kong, Br J Dermatol, 167, 44, 10.1111/j.1365-2133.2012.10894.x

Phillips E, Keane N, Blyth C, Lucas A, Pavlos R, Lucas M, et al. Both HLA Class I restricted CD8+ and class II restricted CD4+ T cells are implicated in the pathogenesis of nevirapine hypersensitivity. 51st ICAAC. Chicago, Ill; September 2011:H1-1399c.

Alfirevic, 2006, HLA-B locus in Caucasian patients with carbamazepine hypersensitivity, Pharmacogenomics, 7, 813, 10.2217/14622416.7.6.813

Pirmohamed, 2001, TNF alpha promoter region gene polymorphisms in carbamazepine-hypersensitive patients, Neurology, 56, 890, 10.1212/WNL.56.7.890

Jonville-Bera, 2009, Strontium ranelate-induced DRESS syndrome: first two case reports, Allergy, 64, 658, 10.1111/j.1398-9995.2009.01940.x

Zhang, 2013, HLA-B*13:01 and the dapsone hypersensitivity syndrome, N Engl J Med, 369, 1620, 10.1056/NEJMoa1213096

Vitezica, 2008, HLA-DRB1*01 associated with cutaneous hypersensitivity induced by nevirapine and efavirenz, AIDS, 22, 540, 10.1097/QAD.0b013e3282f37812

Chantarangsu, 2009, HLA-B*3505 allele is a strong predictor for nevirapine-induced skin adverse drug reactions in HIV-infected Thai patients, Pharmacogenet Genomics, 19, 139, 10.1097/FPC.0b013e32831d0faf

Chantarangsu, 2011, Genome-wide association study identifies variations in 6p21.3 associated with nevirapine-induced rash, Clin Infect Dis, 53, 341, 10.1093/cid/cir403

Romano, 1998, Delayed hypersensitivity to aminopenicillins is related to major histocompatibility complex genes, Ann Allergy Asthma Immunol, 80, 433, 10.1016/S1081-1206(10)62997-3

Hu, 2011, Pilot association study of oxcarbazepine-induced mild cutaneous adverse reactions with HLA-B*1502 allele in Chinese Han population, Seizure, 20, 160, 10.1016/j.seizure.2010.11.014

Lv, 2013, The association between oxcarbazepine-induced maculopapular eruption and HLA-B alleles in a northern Han Chinese population, BMC Neurol, 13, 75, 10.1186/1471-2377-13-75

Hautekeete, 1999, HLA association of amoxicillin-clavulanate–induced hepatitis, Gastroenterology, 117, 1181, 10.1016/S0016-5085(99)70404-X

Lucena, 2011, Susceptibility to amoxicillin-clavulanate-induced liver injury is influenced by multiple HLA class I and II alleles, Gastroenterology, 141, 338, 10.1053/j.gastro.2011.04.001

O'Donohue, 2000, Co-amoxiclav jaundice: clinical and histological features and HLA class II association, Gut, 47, 717, 10.1136/gut.47.5.717

Singer, 2010, A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury, Nat Genet, 42, 711, 10.1038/ng.632

Kindmark, 2008, Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis, Pharmacogenomics J, 8, 186, 10.1038/sj.tpj.6500458

Daly, 2007, Genetic susceptibility to diclofenac-induced hepatotoxicity: contribution of UGT2B7, CYP2C8, and ABCC2 genotypes, Gastroenterology, 132, 272, 10.1053/j.gastro.2006.11.023

Daly, 2009, Genetic association studies in drug-induced liver injury, Semin Liver Dis, 29, 400, 10.1055/s-0029-1240009

Daly, 2012, Genetic association studies in drug-induced liver injury, Drug Metab Rev, 44, 116, 10.3109/03602532.2011.605790

Daly, 2009, HLA-B*5701 genotype is a major determinant of drug-induced liver injury due to flucloxacillin, Nat Genet, 41, 816, 10.1038/ng.379

Spraggs, 2011, HLA-DQA1*02:01 is a major risk factor for lapatinib-induced hepatotoxicity in women with advanced breast cancer, J Clin Oncol, 29, 667, 10.1200/JCO.2010.31.3197

Pellicano, 1994, Genetic susceptibility to fixed drug eruption: evidence for a link with HLA-B22, J Am Acad Dermatol, 30, 52, 10.1016/S0190-9622(94)70007-9

Pellicano, 1997, Fixed drug eruptions with feprazone are linked to HLA-B22, J Am Acad Dermatol, 36, 782, 10.1016/S0190-9622(97)80347-7

Ozkaya-Bayazit, 2001, Fixed drug eruption induced by trimethoprim-sulfamethoxazole: evidence for a link to HLA-A30 B13 Cw6 haplotype, J Am Acad Dermatol, 45, 712, 10.1067/mjd.2001.117854

Lieberman, 1990, HLA-B38, DR4, DQw3 and clozapine-induced agranulocytosis in Jewish patients with schizophrenia, Arch Gen Psychiatry, 47, 945, 10.1001/archpsyc.1990.01810220061007

Valevski, 1998, HLA-B38 and clozapine-induced agranulocytosis in Israeli Jewish schizophrenic patients, Eur J Immunogenet, 25, 11, 10.1046/j.1365-2370.1998.00091.x

Athanasiou, 2011, Candidate gene analysis identifies a polymorphism in HLA-DQB1 associated with clozapine-induced agranulocytosis, J Clin Psychiatry, 72, 458, 10.4088/JCP.09m05527yel

Dettling, 2007, Clozapine-induced agranulocytosis in schizophrenic Caucasians: confirming clues for associations with human leukocyte class I and II antigens, Pharmacogenomics J, 7, 325, 10.1038/sj.tpj.6500423

Diez, 1990, HLA-B27 and agranulocytosis by levamisole, Immunol Today, 11, 270, 10.1016/0167-5699(90)90109-M

Batchelor, 1980, Hydralazine-induced systemic lupus erythematosus: influence of HLA-DR and sex on susceptibility, Lancet, I, 1107, 10.1016/S0140-6736(80)91554-8

Vedove, 2009, Drug-induced lupus erythematosus, Arch Dermatol Res, 301, 99, 10.1007/s00403-008-0895-5

Kim, 2008, Pharmacogenetics of aspirin-intolerant asthma, Pharmacogenomics, 9, 85, 10.2217/14622416.9.1.85

Rodriguez-Perez, 1994, Association of HLA-DR5 with mucocutaneous lesions in patients with rheumatoid arthritis receiving gold sodium thiomalate, J Rheumatol, 21, 41

Speerstra, 1985, HLA associations in aurothioglucose- and D-penicillamine-induced haematotoxic reactions in rheumatoid arthritis, Tissue Antigens, 26, 35, 10.1111/j.1399-0039.1985.tb00932.x

Quiralte, 1999, Association of HLA-DR11 with the anaphylactoid reaction caused by nonsteroidal anti-inflammatory drugs, J Allergy Clin Immunol, 103, 685, 10.1016/S0091-6749(99)70243-5

Garlepp, 1983, HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis, Br Med J (Clin Res Ed), 286, 1442, 10.1136/bmj.286.6375.1442-a

Pachoula-Papasteriades, 1986, HLA-A,-B, and -DR antigens in relation to gold and D-penicillamine toxicity in Greek patients with RA, Dis Markers, 4, 35

Maier, 2003, Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease, J Immunol, 171, 6910, 10.4049/jimmunol.171.12.6910

Rosenman, 2011, HLA class II DPB1 and DRB1 polymorphisms associated with genetic susceptibility to beryllium toxicity, Occup Environ Med, 68, 487, 10.1136/oem.2010.055046

Morito, 2012, Drug eruption with eosinophilia and systemic syndrome associated with reactivation of human herpesvirus 7, not human herpesvirus 6, J Dermatol, 39, 669, 10.1111/j.1346-8138.2011.01365.x

Descamps, 1997, Human herpesvirus 6 infection associated with anticonvulsant hypersensitivity syndrome and reactive haemophagocytic syndrome, Br J Dermatol, 137, 605, 10.1111/j.1365-2133.1997.tb03795.x

Kawakami, 2009, Drug-induced hypersensitivity syndrome: drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome induced by aspirin treatment of Kawasaki disease, J Am Acad Dermatol, 60, 146, 10.1016/j.jaad.2008.07.044

Hamaguchi, 2010, Intractable genital ulcers from herpes simplex virus reactivation in drug-induced hypersensitivity syndrome caused by allopurinol, Int J Dermatol, 49, 700, 10.1111/j.1365-4632.2009.04441.x

Mardivirin, 2010, Amoxicillin-induced flare in patients with DRESS (drug reaction with eosinophilia and systemic symptoms): report of seven cases and demonstration of a direct effect of amoxicillin on Human Herpesvirus 6 replication in vitro, Eur J Dermatol, 20, 68, 10.1684/ejd.2010.0821

Tamagawa-Mineoka, 2007, DRESS syndrome caused by teicoplanin and vancomycin, associated with reactivation of human herpesvirus-6, Int J Dermatol, 46, 654, 10.1111/j.1365-4632.2007.03255.x

Draz, 2013, Drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome secondary to antituberculosis drugs and associated with human herpes virus-7 (HHV-7), BMJ Case Rep. July 31,, 10.1136/bcr-2013-010348

Funck-Brentano, 2011, Auto-immune thyroiditis and drug reaction with eosinophilia and systemic symptoms (DRESS) associated with HHV-6 viral reactivation [in French with English abstract], Ann Dermatol Venereol, 138, 580, 10.1016/j.annder.2011.01.048

Sandouk, 2012, DRESS syndrome and thrombotic thrombocytopaenic purpura: are they related?, BMJ Case Rep. November 14,, 10.1136/bcr-2012-007558

Kinyo, 2011, Strontium ranelate-induced DRESS syndrome with persistent autoimmune hepatitis, Acta Derm Venereol, 91, 205, 10.2340/00015555-1014

Bejia, 2006, DRESS syndrome induced by sulphasalazine in rheumatoid arthritis, Joint Bone Spine, 73, 764, 10.1016/j.jbspin.2006.01.006

Michel, 2005, DRESS syndrome in a patient on sulfasalazine for rheumatoid arthritis, Joint Bone Spine, 72, 82, 10.1016/j.jbspin.2004.06.002

Pinana, 2010, DRESS-syndrome on sulfasalazine and naproxen treatment for juvenile idiopathic arthritis and reactivation of human herpesvirus 6 in an 11-year-old Caucasian boy, J Clin Pharm Ther, 35, 365, 10.1111/j.1365-2710.2009.01081.x